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ResolutionExtracellular ATP is an important signaling molecule throughout the inﬂammatory cascade, serving
as a danger signal that causes activation of the inﬂammasome, enhancement of immune cell inﬁl-
tration, and ﬁne-tuning of several signaling cascades including those important for the resolution of
inﬂammation. Recent studies demonstrated that ATP can be released from cells in a controlled man-
ner through pannexin (Panx) channels. Panx1-mediated ATP release is involved in inﬂammasome
activation and neutrophil/macrophage chemotaxis, activation of T cells, and a role for Panx1 in
inducing and propagating inﬂammation has been demonstrated in various organs, including lung
and the central and peripheral nervous system. The recognition and clearance of dying cells and
debris from focal points of inﬂammation is critical in the resolution of inﬂammation, and Panx1-
mediated ATP release from dying cells has been shown to recruit phagocytes. Moreover, extracellu-
lar ATP can be broken down by ectonucleotidases into ADP, AMP, and adenosine, which is critical in
the resolution of inﬂammation. Together, Panx1, ATP, purinergic receptors, and ectonucleotidases
contribute to important feedback loops during the inﬂammatory response, and thus represent
promising candidates for new therapies.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
1.1. Induction and resolution of inﬂammation
The inﬂammatory response is involved in many diseases and
provides many opportunities for the development of new thera-
pies. A typical inﬂammatory response begins when cells recognize
pathogen-associated molecular patterns (PAMPs) via pattern rec-
ognition receptors such as toll-like receptors (TLR) or RIG1 [1].
These danger signals induce expression of inﬂammatory genes
and chemokines, which perpetuate pro-inﬂammatory signaling
[1]. Immune cells such as neutrophils and macrophages are re-
cruited to the site of inﬂammation to clear away pathogens as well
as dying cells [2]. Following the initial innate immune response,
macrophages, dendritic cells, and other cells present antigenic pep-
tides on MHC class II molecules, resulting in the activation of T
cells and the subsequent generation of an adaptive immune
response that further combats infection [2]. Less is known about
how the inﬂammatory response is resolved. Resolution of inﬂam-
mation is an active process that involves dampening of inﬂamma-
tory cytokine production, clearance of apoptotic cells, and the
phenotypic switching of macrophages to anti-inﬂammatoryphenotypes that are capable of tissue repair [3–5]. The ability of
cells that initially respond to danger signals, such as neutrophils,
to undergo apoptosis as opposed to necrosis is an important aspect
of resolution of inﬂammation because the apoptotic pathway lim-
its leakage of additional danger signals into the extracellular space
[6–8]. Additionally, the ability of macrophages and other phago-
cytes to recognize and phagocytose the apoptotic cells is critical
for the appropriate resolution of inﬂammation [6,8].
1.2. Extracellular ATP as a danger signal: recognition by purinergic
receptors
Extracellular ATP is an important signalingmolecule throughout
the inﬂammatory cascade, serving as a danger signal that causes
activation of the inﬂammasome [9], enhancement of immune cell
inﬁltration [10], and ﬁne-tuning of several signaling cascades
including those important for the resolution of inﬂammation [11].
Extracellular ATP is a ligand for several purinergic receptors which
includes P2X1–7 (ATP-gated cation channels) and P2Y receptors
1,2,4,6,11–14 (G-protein coupled receptors; most are Gi or Gq cou-
pled) [12]. X-ray structures of P2X receptors have recently been ob-
tained which have greatly increased our knowledge of how ATP
binds to and activates these cation channels [13,14]. P2X receptors
exclusively bind ATP as a ligand, while certain P2Y receptors have
afﬁnity for ATP as well as UTP, ADP, UDP or UDP-glucose [12].
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example, the EC50 of ATP for P2X7 receptor (>100 lM) is nearly
two orders of magnitude higher than the EC50 of ATP for P2X1–6
[12]. It is important to keep in mind the amount of extracellular
ATP available for signaling in a given situation as it impacts which
purinergic receptors are likely to be activated.
After being released from cells, ATP can be broken down by cell
surface ectonucleotidases into ADP, AMP, and adenosine [12]. As
mentioned above, ADP has varying afﬁnities for certain P2Y recep-
tors while adenosine binds and signals through adenosine recep-
tors which include A1, A2a, A2b, and A3 [12]. The breakdown of
extracellular ATP can be considered a mechanism of limiting ATP
signaling or a mechanism of initiating signaling by breakdown
products such as adenosine. There are four families of ectonucleo-
tidases in mammalian cells which can breakdown extracellular
ATP: the ectonucleoside triphosphate diphosphohydrolase
(ENTPD) family, the ectonucleotide pyrophosphatase/phosphodi-
esterase (ENPP) family, the alkaline phosphatase family, and
ecto-50-nucleotidase (also known as CD73) [12].
1.3. Mechanisms of ATP release by pannexin1 (Panx1) during
inﬂammation
Previously, the source of extracellular ATP was thought to be so-
lely from damaged and necrotic cells releasing their intracellular
contents [15], or via vesicular release mechanisms [16], but recent
studies demonstrated that ATP can be released in a controlled
manner through hemichannels such as pannexins and connexins
[17–20]. Connexin hemichannels contribute to inﬂammation
through regulation of leukocyte adhesion to the endothelium,
and while connexin-mediated release of ATP and other molecules
is similar to that of pannexins, connexins also mediate gap junc-
tional intercellular communication [21]. Pro-inﬂammatory stimuli
decrease the expression of Cx40 and increase expression of Cx43.
The activity of the ectonucleotidase CD73 is lowered in the absence
of Cx40 such that extracellular ATP levels increase and signal
through purinergic receptors to mobilize intracellular calcium sig-
naling that is propagated through the connexin gap junction net-
work in the endothelium, resulting in increased expression of
endothelial adhesion molecules for leukocytes [21]. In the central
nervous system, microglial have been reported to release gluta-
mate via connexin hemichannels, which may contribute to gluta-
mate excito-neurotoxicity, yet it has also been reported that the
connexin gap junctional intercellular communication network in
astrocytes serves as a sink for excess glutamate [21].
The focus of this review will be the pannexin hemichannels. The
three members of the pannexin family, Panx1–3, are hexameric
plasma membrane channels, structurally similar to connexins but
not gap-junction-forming [22]. Panx1 and 3 are present in many
tissues while Panx2 is mainly expressed in the brain [11]. The func-
tion of Panx2 and Panx3 channels is reviewed elsewhere [17].
Panx1 channels located on the plasma membrane release ATP,
other nucleotides, and molecules up to 1 kD, into the extracellular
space, when activated [17]. Panx1 channels have also been ob-
served to be present on the endoplasmic reticulum, functioning
as intracellular calcium-leak channels [23]. Pannexin channels
are post-translationally modiﬁed by N-glycosylation [24] and they
can also be S-nitrosylated [25], which has important functional
consequences. Regulation of Panx1 expression remains to be fully
studied, but it has been reported that treatment with IL1b upregu-
lates Panx1 expression [26]. Known inhibitors of Panx1 include
carbenoxolone (CBX), probenecid, meﬂoquine, which have other
targets in addition to Panx1, and the food dye FD&C Blue No. 1
which has speciﬁcity for Panx1 [27,28]. Activation of Panx1 can
proceed by various mechanisms including mechano-stretch [29],a1-adrenergic [19] or histamine stimulation [30], and caspase-
mediated cleavage of the C-terminal portion of Panx1, the latter
of which results in an irreversible ‘‘unplugging’’ of the channel pore
[20]. It is important to note that caspase-mediated cleavage and
activation of Panx1 results in irreversible channel opening and pre-
sumably higher amounts of extracellular ATP being released. Panx1
activation can be coupled to purinergic receptor activation as in
the case of inﬂammasome activation, during which P2X7 receptor
and Panx1 are associated. It has also been reported that activation
of P2Y6 receptors in bladder urothelium mediates Panx1-depen-
dent ATP release [31].
The role of pannexins in inﬂammatory diseases is just beginning
to be understood. Here we review the function of pannexin 1 chan-
nels during the inﬂammatory response in several different tissues
and disease models including the nervous system, airway, and
colon.
2. Pannexin channel function during the innate immune
response: inﬂammasome activation and immune cell
recruitment
2.1. Panx1 and the inﬂammasome
Extracellular ATP was shown to activate the NLRP3 inﬂamma-
some, causing the assembly of scaffold components: the cytoplas-
mic receptor NLRP3, the adaptor protein ASC and the effector
protein caspase-1, which becomes activated through this process
[9]. Caspase-1 activation is required for proper maturation and
secretion of the inﬂammatory cytokines IL1b and IL18 [9]. IL1b pro-
duction in some cells requires two signals: (1) TLR signaling to in-
duce expression of pro-IL1b and (2) high levels of extracellular ATP
to signal through purinergic receptors to activate the inﬂamma-
some, producing active caspase-1 to process pro-IL1b into its ma-
ture form. However, it has been shown that certain non-
nucleotide activators such as biglycan [32] and serum amyloid A
[33] also cause inﬂammasome activation by signaling through
purinergic receptors. The most extensively-studied purinergic
receptor involved in the inﬂammasome activation pathway is the
P2X7 receptor which, as stated above, requires >100 lM ATP to be-
come activated [12]. In the context of inﬂammation, one source of
extracellular ATP at concentrations high enough to activate P2X7
receptors is the ATP that spills out from necrotic cells. Another pos-
sibility is that ATP is released in a controlled manner through the
activated Panx1 channels and acts on cells in a paracrine or auto-
crine fashion. Ayna et al. showed that the release of ATP from dying
autophagic cells as they are engulfed by macrophages is crucial for
inﬂammasome activation in macrophages [34]. Moreover, uptake
of particulate uric acid, silica, and alum by macrophages was
shown to cause pannexin/connexin-dependent release of ATP [35].
Pannexin channels have been shown to interact with P2X recep-
tors at the cell membrane. Panx1 associates with P2X7 to create a
large, high-permeability pore at the plasmamembrane [36,37]. The
role of other P2X receptors in inﬂammasome activation has also
been investigated, and it was shown that P2X4 receptor assembles
with P2X7 receptor and Panx1 in epithelial cells and contributes to
ROS generation in response to extracellular ATP [38]. Decreased
extracellular calcium has been implicated as a trigger for the asso-
ciation of P2X7 and Panx1 at the plasma membrane [36], and dif-
ferent splice variants of the P2X7 receptor were shown to have
different coupling capabilities with Panx1 [37].
However, there is also evidence that the high-permeability pore
evident in macrophages after prolonged P2X7 receptor activation
is not dependent on pannexin channels [39]. Moreover, bone mar-
row-derived macrophages from Panx1 null mice in which exon 2 is
deleted to generate a frameshift and premature stop codon had no
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treatment with a variety of inﬂammatory stimuli [40]. He et al.
demonstrated that murine dendritic cells do not require P2X7–
Panx1 for inﬂammasome activation [41]. A live cell imaging study
of murine macrophages revealed that transient (1–4 min) stimula-
tion of high extracellular ATP triggers delayed cell death (over
hours), which was not dependent on Panx1 [42]. Clearly, more
work is required to elucidate the complex interactions between
Panx1 and purinergic receptors, particularly in the case of P2X7-
mediated inﬂammasome activation.
As stated above, ATP-mediated inﬂammasome activation re-
sults in the release of mature cytokines and occurs in a wide vari-
ety of tissues, particularly in settings of acute tissue injury and
infection. Bleomycin-induced release of ATP by pulmonary epithe-
lial cells in a murine model of lung inﬂammation signals through
P2X7 receptor resulting in the activation of inﬂammasome and in-
creased secretion of IL1b. In vitro, Panx1 inhibitors block this re-
lease of ATP indicating that Panx1 is at least partially responsible
for this process [43]. These investigators also showed increased
ATP content in bronchoalveolar lavage ﬂuid from patients with idi-
opathic pulmonary ﬁbrosis [43]. During sepsis, P2X7–Panx1-
dependent inﬂammasome activation results in the release of high
mobility group box 1 (HMGB1), which activates macrophages
and causes cytokine release, perpetuating inﬂammation [44]. Using
the cecal ligation and puncture model of polymicrobial sepsis in
mice, the authors demonstrated that treatment with the Panx1
inhibitor carbenoxolone signiﬁcantly reduced circulating and per-
itoneal HMGB1 levels and promoted a signiﬁcant increase in ani-
mal survival rates [44]. Negoro et al. showed IL1b upregulation
did not occur in Panx1 null mice in a model of bladder dysfunction
in multiple sclerosis [26].
2.2. Panx1 and cell migration
In addition to inﬂammasome activation, extracellular ATP
guides the chemotaxis of neutrophils [45] and macrophages [46]
by signaling through various purinergic receptors [10]. Extracellu-
lar ATP impacts neutrophil migration by amplifying chemotactic
signals through P2 receptors [45,47,48]. In this context, Panx1
mediated release of ATP was shown to be important in both the
front and back edge rufﬂing of neutrophils. This helps synergize
and ﬁne-tune chemotactic responses and thus allows coordinated
cell movement [49]. ATP released by dying cells is a chemoattrac-
tant for macrophages via the activation of P2Y2 receptors [50].
Panx1 mediates ATP release from apoptotic cells as a ‘‘ﬁnd-me’’
signal for phagocytes [18]. Other groups have shown that ATP-in-
duced activation of certain P2Y receptors causes non-directional
movement of immune cells, speciﬁcally macrophages [51]. In sup-
port of a role for Panx1-dependent ATP release in leukocyte migra-
tion, Qu et al. demonstrated that Panx1 null thymocytes were
unable to recruit peritoneal macrophages in a Transwell migration
assay [40]. Furthermore, Oishi et al. showed that Panx activation
and ATP release frommurine atrial myocytes induced by mechano-
stretch caused macrophage migration in a Transwell assay [52]. In
this case, Panx2, not Panx1 appeared responsible for the phenotype
because the atrial myocyte cell line (HL-1) did not express Panx1
and the siRNA-mediated knockdown of Panx2 with siRNA de-
creased migration of macrophages and ATP release [52].
It was shown that P2X7 and Panx1 were both required for the
generation of multinucleated macrophages induced by the inﬂam-
matory cytokine GM-CSF [53]. However, extracellular ATP release
was dependent on the P2X7 receptor rather than Panx1 expression,
and the metabolism of released ATP to adenosine was shown to
mediate P2X7-dependent macrophage fusion [53].Together, a number of studies show that controlled release of
ATP via Panx1 is a key mechanism important for initiating inﬂam-
matory signaling and also for the recruitment of leukocytes.
Although the levels of extracellular ATP generated in vivo are difﬁ-
cult to analyze, ﬂuctuations in extracellular ATP levels are likely to
determine the relative involvement of various purinergic receptor
subtypes.
3. Pannexin channel function during adaptive immunity: Panx1
and T cell function
Extracellular ATP has been shown to play an important role in
adaptive immunity, speciﬁcally in T cell function. T cell receptor
stimulation was shown to be sustained through a feedback loop
involving ATP released by Panx1 acting back on P2 receptors to
maintain MAPK signaling [54]. Woehrle et al. went on to show that
this TCR signaling feedback loop is mediated by Panx1-dependent
release of ATP which acts speciﬁcally on P2X1 and P2X4 receptors
on the T cell surface [55]. The same group demonstrated the clinical
relevance of these ﬁndings. Hypertonic saline is often administered
to trauma patients with T cell suppression that are at high risk of
posttraumatic infectious complications and sepsis. The authors
showed that hypertonic saline induces Panx1 activation and the
subsequent ATP release enhances T cell function [56]. The elimina-
tion of extracellular ATP signaling by ectonucleotidases appears to
be an importantmechanism throughwhich regulatory T (Treg) cells
mediate their immunesuppresive and homeostatic function [57].
Patients with relapsing-remitting multiple sclerosis, an inﬂamma-
tory autoimmune disease, have strikingly reduced numbers of Treg
cells that express the ectonucleotidase CD39 [57]. The role of pann-
exin channels in Treg cell function has yet to be explored.
An extracellular ATP signaling loop involving Panx1 and P2
receptors plays a role in HIV infection of T cells. Seror et al. showed
that the interaction of HIV1 envelop protein with target receptors
on T cells caused ATP release from Panx1. Subsequent signals
through P2Y2 receptor mediated Pyk2 kinase activation and plas-
ma membrane depolarization to stimulate the fusion between
Env-expressing membranes and membranes containing CD4 plus
appropriate chemokine co-receptors [58]. Purinergic receptors,
namely P2X1, have also been shown to be required for HIV-1 infec-
tion of primary human macrophages [59]. In contrast, Barat et al.
found that extracellular ATP had no effect on direct CD4+ T cell
infection, but reduced HIV-1 transfer from immature dendritic
cells to CD4+ T cells [60]. The Panx1–P2 receptor pathway repre-
sents novel and exciting new targets for HIV1 therapy.
Extracellular ATP signaling impacts dendritic cell function by
modulating the production of certain cytokines and chemokines
including MCP1/CCL2, MiP1a, IL12, IL10, and IL27, IL23 to favor a
Th2 response or tolerance [61–64]. In an asthmatic airway model
in mice, extracellular ATP recruits and activates lung myeloid den-
dritic cells that induce Th2 responses in the mediastinal nodes
[65,66]. Hepatic dendritic cells that lack the ectonucleotidase
CD39 have stronger proinﬂammatory and immunostimulatory
activity [67]. In cancer models, extracellular ATP increases the abil-
ity of dendritic cells to present tumor-associated antigens [68].
While the role of pannexin in mediating extracellular ATP signaling
to dendritic cells remains to be investigated, Panx1-mediated ATP
release may occur in an autocrine fashion as has been shown in T
cells, but may also occur in a paracrine fashion between dendritic
cells and T cells.
Although much work has been done on the regulation of im-
mune cells by extracellular ATP (reviewed in Jacob et al. [69]),
the role of Panx1 in controlling immune responses remains to be
established. To fully understand the role of Panx1 in adaptive
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Panx1 knockout mice are needed. There is evidence that the role of
extracellular ATP in immunoregulation is even more complex in
humans and that patterns of purinergic receptor expression differ
between mice and humans [70].
4. Neural inﬂammation and pannexin 1
Pannexins are highly expressed in the brain and peripheral
nerves [17]. Panx1 can be activated in neurons and astrocytes by
high extracellular potassium [71] and by ATP activation of P2
receptors [72,73]. Panx1-mediated ATP release in the nervous sys-
tem occurs in the context of inﬂammation [72]. Garre et al. demon-
strated a feedback loop in which FGF1 (ﬁbroblast growth factor)
signaling through FGFR induces spinal astrocytes to release ATP
vesicularly, which feeds back onto P2 receptors to cause subse-
quent Panx1 activation and ATP release, and hours later connexin
hemichannels open and release ATP [74]. The self-sustaining ATP
release through multiple channels allows for a sustained inﬂam-
matory response, which can be detrimental; for example, in the
case of a murine spinal cord injury model, blocking FGF1 receptor
to block ATP release is associated with decreased recruitment or
microglia andmacrophages and decreased secondary lesion expan-
sion [74]. Another inﬂammatory feedback loop between astrocytes
and neurons was shown in a co-culture model where ATP and glu-
tamate released from astrocytes treated with conditioned media
from inﬂammatory microglia activated neuronal Panx1 channels,
resulting in neuron death [72,73]. In this system, inhibition of
NMDA and P2X receptors blocked Panx1 function; however, block-
ing astroglial Panx1 had no effect, indicating that it is the neuronal
Panx1 that is important [73].
Panx1-mediated ATP release and subsequent neuronal cell
death has also been shown to occur in the pathology of glaucoma
during which signals downstream of stretching- or swelling-in-
duced activation of Panx1–P2X7 inﬂuence dendritic and axonal
remodeling that may lead to retinal ganglion cell death [75].
In an experimental model of retinal ischemic-reperfusion
injury, ablation of Panx1 protects retinal neurons from ischemic
injury due to suppression of IL1b production and inﬂammasome
activation [76].
Panx1-mediated neuronal cell death has also been demon-
strated in a colitis model where activation of neuronal P2X7–Panx1
mediates the death of enteric neurons [77]. This work followed up
on interesting observations made by Diezmos et al. in human pa-
tients with Crohn’s disease where they showed decreased Panx1
mRNA and protein levels in the muscularis layer of the colon com-
pared to control patients [78]. Colons from patients with ulcerative
colitis revealed reduced Panx1 immunoreactivity in the myenteric
ganglia [78].
Activated microglia can initiate an ATP signaling cascade in the
context of inﬂammation that ultimately results in neuronal death,
and recent work demonstrates an ATP-mediated feedback loop be-
tween resting microglia and active neurons [79,80]. Resting
microglia project highly motile processes into the surrounding
neural tissue in order to survey the tissue. Neuronal activity regu-
lates the dynamics of resting microglial processes and the forma-
tion of microglia-neuron contact. Communication between active
neurons and resting microglia can be mediated by neuronal ATP
release via Panx1, as was demonstrated in a larval zebra ﬁsh
model in the optic tectum, which is the visual center of the organ-
ism [79,80]. In vivo whole cell recordings in the larva revealed
functional Panx1 channels were expressed in tectal neurons but
not microglia [79,80] Bulbous microglial process contact formation
was decreased with the Panx1 inhibitors probenecid and carbenox-olone, genetic downregulation of Panx1, ATP degradation with
apyrase, and the pan P2R inhibitor suramin [79,80].
Together these studies establish a role for Panx1 in neural
inﬂammation in which activation of neural Panx1 leads to neuro-
nal cell death, both in the brain and in the periphery. It would seem
that in these models, Panx1 is being irreversibly activated since
activation leads to cell death as opposed to temporary activation
and ATP release, which modulates cell function as in the case of
T cells. More research is needed to determine the mechanisms of
Panx1 activation in physiologic contexts. Moreover, the particular
cells types in which Panx1 contributes to signaling remains to be
determined. The use of conditional knockout animals and in vivo
experimental disease models will greatly expand our understand-
ing of how Panx1 contributes to neural inﬂammation.
5. Role of pannexin 1 in resolution of inﬂammation
Clearly, extracellular ATP is a danger signal that helps initiate
the inﬂammatory response through activation of the inﬂamma-
some and recruitment of immune cells; however, growing evi-
dence suggests that it also plays a role in the resolution of
inﬂammation. The recognition and clearance of dying cells and
debris from focal points of inﬂammation is critical in the resolution
of inﬂammation [81,8]. Several groups have demonstrated the role
of ATP in the chemotaxis of immune cells toward damaged cells,
which require clearance [46,50]. A role for Panx1 in releasing
ATP in the context of cell clearance has been demonstrated
[8,18]. The consequences of defects in Panx1-mediated cell clear-
ance in various disease models remain to be shown.
Resolution of inﬂammation depends upon the decrease of
inﬂammatory cytokine production as well as the increase of anti-
inﬂammatory cytokines or wound healing factors. P2X7 receptor
signalingwas shown to contribute to the resolution of inﬂammation
by stimulating the release the proangiogenic factor VEGF from
monocytes, which is critical for wound repair [11]. Pyrophosphates,
which are products of extracellular ATP breakdown, can dampen
NLR andTLR-mediated inﬂammatory signaling [82]. Genes that con-
trol extracellular ATPmetabolism have been found to be novel anti-
inﬂammatory M2 macrophage-associated markers [82].
Another product of extracellular ATP breakdown known to play
a role in the resolution of inﬂammation is adenosine. In a model of
murine colonic inﬂammation, CD73, a GPI-linked membrane pro-
tein that catalyzes the dephosphorylation of AMP to adenosine
extracellularly, was shown to be critical for the resolution of
inﬂammation [83]. Adenosine A2B receptor signaling was shown
in cultured human intestinal epithelial cells as well as murine coli-
tis models to be protective against inﬂammation due to the stimu-
lation of IL10 production [84]. Consequently, adenosine receptor
agonism has been shown to improve lung function in rodent mod-
els of acute lung injury [85]. Adenosine A2A receptors have been
shown to play a role in engulfment-dependent apoptotic cell sup-
pression of inﬂammation [86], and adenosine is also a signiﬁcant
mediator of regulatory T cell function [87]. It remains to be deter-
mined whether controlled ATP release by Panx1 contributes to res-
olution either through direct signaling by ATP or signaling of ATP
breakdown products.
6. Outlook
Panx1, ATP, purinergic receptors, and ectonucleotidases con-
tribute to important feedback loops during the inﬂammatory re-
sponse (Fig. 1). The members of these feedback loops are
promising candidates for new therapies. Small molecular inhibitors
of P2X and P2Y receptors are actively being researched for the
Fig. 1. Roles of Panx1 during the different phases of the inﬂammatory response. During the initiation phase of inﬂammation, ATP released by Panx1 is a danger signal, which
activates the inﬂammasome through signaling to purinergic P2X receptors, resulting in cytokine production. Panx1 channel function also directs immune cell chemotaxis
through various purinergic receptors. Irreversible activation of Panx1 results in cell death, especially in neurons. During adaptive immunity, Panx1-dependent ATP release
mediates a feedback loop on T cells. Extracellular ATP is known to activate dendritic cells, but the involvement of Panx1 remains to be determined. Clearance of apoptotic cells
is crucial for the resolution of inﬂammation, and Panx1-dependent nucleotide release is involved in this process. Breakdown products of ATP such as adenosine are well-
known mediators of anti-inﬂammation and resolution, and controlled release of ATP by Panx1 may increase adenosine levels through the action of ectonucleotidases.
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inﬂammation [91,92], status epilepticus [93], and other diseases.
Although much more research is required, Panx1 as a drug target
is promising as evidenced by murine disease models in which
treatment with Panx1 inhibitors such as carbenoxolone have
yielded beneﬁt. However, more speciﬁc inhibitors of Panx1 are
desperately needed. Carbenoxolone also inhibits connexins and
other targets, as do probenicid and meﬂoquine. It is tantalizing that
both probenicid and meﬂoquine have been used by patients for
many years as treatment of gout and malaria, respectively. Analy-
sis of data from patients treated with these drugs may yield
increasing evidence of the beneﬁts or disadvantages of Panx1 inhi-
bition. The development of conditional Panx1 knockout mice and
their use in murine models of disease and the validation of murine
ﬁndings in human cells and tissues will greatly aid in determining
the role of Panx1 in the induction and resolution of inﬂammation.
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